AI-POCUS for Maternal and Neonatal Health in Ethiopia

NCT ID: NCT07171086

Last Updated: 2025-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

1059 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-30

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Maternal and neonatal health remains one of the most pressing global health challenges, particularly in low- and middle-income countries (LMICs). Ethiopia continues to face a high burden, with maternal mortality estimated at 195 per 100,000 live births, neonatal mortality at 27 per 1,000 live births, and perinatal mortality rates ranging from 37‰ to 124‰ depending on the level of care. These outcomes remain substantially higher than the targets set under the United Nations Sustainable Development Goals (SDGs) for 2030.

The World Health Organization (WHO) recommends that all pregnant women receive at least one ultrasound scan before 24 weeks of gestation, yet nearly two-thirds of women worldwide-especially in LMICs-lack access to this service. Barriers include high costs of ultrasound machines, limited technical expertise, and shortages of skilled sonographers in rural primary care.

Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) represents a promising innovation to expand prenatal imaging in resource-constrained settings by equipping frontline health workers with AI-supported diagnostic capabilities. This study, conducted under the Tsinghua University BRIGHT (Bringing Research to Impact for Global Health at Tsinghua) program, will evaluate the clinical effectiveness, feasibility, cost, and scalability of AI-POCUS in rural Ethiopia. A three-arm cluster randomized controlled trial will compare two AI-enabled ultrasound technologies-BabyChecker (Netherlands) and a China-developed AI-POCUS device-against standard antenatal care without ultrasound. Findings will generate robust clinical and policy-relevant evidence to guide the sustainable implementation of AI-enabled maternal health interventions in sub-Saharan Africa.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Maternal and neonatal morbidity and mortality remain unacceptably high in sub-Saharan Africa and continue to impede progress toward global health targets. In Ethiopia, recent estimates show maternal mortality at 195 per 100,000 live births and neonatal mortality at 27 per 1,000 live births. Perinatal mortality is also elevated, ranging between 66‰ and 124‰ in hospital-based settings and 37‰ to 52‰ in community-level health facilities. These figures surpass the Sustainable Development Goal (SDG) thresholds for 2030, underscoring the urgent need for innovative, scalable solutions.

Ultrasound imaging is a cornerstone of modern antenatal care. The WHO recommends at least one ultrasound before 24 weeks' gestation to assess gestational age, detect multiple pregnancies, identify fetal anomalies, and diagnose high-risk conditions such as preeclampsia, placenta previa, or growth restriction. However, nearly two-thirds of pregnant women worldwide still lack access to this basic diagnostic tool. In low-resource environments, the barriers include limited infrastructure, high equipment costs, technical complexity, and the scarcity of trained professionals capable of performing and interpreting scans. As a result, potentially preventable maternal and neonatal deaths remain common.

Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) introduces a transformative opportunity to address these gaps. POCUS devices embedded with AI algorithms can guide non-specialist health workers in image acquisition and interpretation, reducing reliance on highly trained personnel and lowering barriers to integration within primary care. Such innovations may strengthen early detection of pregnancy complications, enable timely referral to higher-level care, and ultimately improve maternal and neonatal survival.

This study is embedded within the Bringing Research to Impact for Global Health at Tsinghua (BRIGHT) initiative. It will use a three-arm cluster randomized controlled trial (C-RCT) design to evaluate and compare: (1) BabyChecker, a portable AI-enabled ultrasound developed in the Netherlands, (2) A China-developed AI-POCUS device, and (3) Standard antenatal care (ANC) without ultrasound, reflecting current practice in many rural Ethiopian communities.

The study population will include pregnant women receiving antenatal care in rural Ethiopia, as well as primary health care providers delivering these services. Data will be collected at both the patient and facility level to capture maternal and neonatal health outcomes, health service utilization, and system-level performance indicators.

Evaluation will follow a multi-dimensional framework, addressing:

1. Clinical effectiveness: improved detection of high-risk pregnancies, reduced maternal and neonatal complications, and mortality.
2. Implementation feasibility and acceptability: user experience among health workers and pregnant women, integration into routine workflows, and perceived trust in AI-assisted care.
3. Economic evaluation: cost and cost-effectiveness of AI-POCUS compared to standard ANC, including resource utilization, referral patterns, and potential savings from earlier detection.
4. Scalability and policy relevance: analysis of barriers and enablers for broader adoption in Ethiopia and similar LMIC contexts, with direct input from policymakers and health system stakeholders.

The study aims to provide rigorous clinical evidence and practical implementation guidance on how AI-POCUS technologies can be sustainably scaled in resource-constrained settings. Findings are expected to inform national health policies, guide investment decisions, and offer a replicable model for expanding maternal health technologies across sub-Saharan Africa and other LMICs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Pregnancy Complications Preterm Birth Fetal Growth Restriction Stillbirth and Fetal Death Pregnancy Abnormal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study will employ a cluster randomized controlled trial design, with primary health care centers serving as the cluster (intervention) units and individual pregnant women as the primary observational units. A total of nine health centers will be selected and matched based on geographic location, maternal mortality rates, and the service capacity of health care personnel. The matched health centers will then be randomly assigned in a 1:1:1 ratio to one of three study arms, with each arm including three health centers.

A total of 1,059 pregnant women will be recruited, with 353 participants per study arm. Interventions will be implemented at the cluster level, while outcomes - including maternal and neonatal health indicators - will be assessed at the individual participant level. This design allows for the evaluation of the effectiveness and feasibility of AI-POCUS interventions while accounting for intra-cluster correlation and contextual variability across health centers.
Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Outcome Assessors
Other parties masked in this trial include the data analysts, who will remain blinded to group assignments during statistical analyses to minimize bias in outcome assessment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Care Control

Participants in this arm will receive routine antenatal care (ANC) according to Ethiopian national guidelines, without the use of AI-POCUS devices. All examinations, screenings, and referrals will be conducted through standard clinical practice. This group serves as the baseline comparator for evaluating the added impact of AI-POCUS technology.

Group Type NO_INTERVENTION

No interventions assigned to this group

BabyChecker (Delft Imaging, Netherlands)

Health centers in this arm will be equipped with the BabyChecker system developed by Delft Imaging (Netherlands). The portable device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, and provides diagnostic suggestions and risk alerts. After brief training, primary healthcare workers will independently perform antenatal examinations, screen for obstetric complications, and make referral decisions.

Group Type EXPERIMENTAL

AI-POCUS (BabyChecker, Delft Imaging)

Intervention Type DEVICE

A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.

AI-POCUS (Edan, China)

This arm will use the AI-POCUS device developed by Edan (China), designed to analyze blind ultrasound sweeps and automatically extract fetal diagnostic parameters. The system supports the early detection of maternal and fetal risks and assists in clinical decision-making.

Group Type EXPERIMENTAL

AI-POCUS (Edan, China)

Intervention Type DEVICE

An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AI-POCUS (BabyChecker, Delft Imaging)

A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.

Intervention Type DEVICE

AI-POCUS (Edan, China)

An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 15-49 years;
2. Gestational age less than 24 weeks at the first ANC visit;
3. No history of severe pregnancy complications (e.g., placenta previa, preeclampsia, etc.);
4. Signed informed consent and agreed to participate in the study.

Exclusion Criteria

1. Pregnant women with cognitive impairments or unable to communicate effectively;
2. Failure to complete antenatal care within the specified timeframe;
3. Incomplete or unavailable records of antenatal care and delivery.
Minimum Eligible Age

15 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Debre Berhan University

OTHER

Sponsor Role collaborator

Tsinghua University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuxuan LI

Doctoral Candidate

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kun TANG, Associate Professor

Role: STUDY_CHAIR

Tsinghua University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hakim Gizaw Hospital

Debre Berhan, Amhara, Ethiopia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Ethiopia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuxuan LI, Doctoral Candidate

Role: CONTACT

+86-18813076657

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tesfanesh Demisse

Role: primary

+251910901201

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BRIGHT (202430045)

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

PROJECT #: BRIGHT (202430045)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.